Metformin HCl | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Metformin HCl
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Arlanda is your partner for the Brazil market.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Metformin HCl

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

109 API Suppliers, 56 USDMF, 42 CEP/COS, 13 JDMF, 29 EU WC, 96 KDMF, 40 NDC API, 43 Listed Suppliers, $ API Reference Price

109 API Suppliers
56 USDMF
42 CEP/COS
13 JDMF
29 EU WC
96 KDMF
40 NDC API
43 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

32 Drugs in Development

32 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1886 FDF Dossiers, 417 FDA Orange Book, 545 Europe, 131 Canada, 122 Australia, 120 South Africa, 551 Listed Dossiers

1886 FDF Dossiers
417 FDA Orange Book
545 Europe
131 Canada
122 Australia
120 South Africa
551 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;1GM, TABLET;ORAL - 2.5MG;500MG, TABLET;ORAL - 2.5MG;850MG, TABLET;ORAL - EQ 12.5MG BASE;1GM, TABLET;ORAL - EQ 12.5MG BASE;500MG, TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG, TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG, TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG, TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE, TABLET;ORAL - 1GM;EQ 50MG BASE, TABLET;ORAL - 500MG;EQ 50MG BASE, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;1GM
TABLET;ORAL - 2.5MG;500MG
TABLET;ORAL - 2.5MG;850MG
TABLET;ORAL - EQ 12.5MG BASE;1GM
TABLET;ORAL - EQ 12.5MG BASE;500MG
TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG
TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG
TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG
TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE
TABLET;ORAL - 1GM;EQ 50MG BASE
TABLET;ORAL - 500MG;EQ 50MG BASE
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 8 Evonik, 8 Rochem International Inc, 23 SPI Pharma, 19 DKSH, 2 Pharm-RX Chemical, 10 Faran Shimi Pharmaceutical, 13 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 9 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Pramukh Pharmachem, 1 ACG Worldwide, 12 Actylis, 3 Aeon Procare, 3 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 38 BASF, 1 Bioplus Life Sciences, 2 Clariant, 27 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 22 Microlex e.U, 2 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 12 Pluviaendo, 6 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 35 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

123 Fillers, Diluents & Binders, 68 Coating Systems & Additives, 56 Controlled & Modified Release, 53 Thickeners and Stabilizers, 52 Direct Compression, 51 Disintegrants & Superdisintegrants, 48 Solubilizers, 43 Taste Masking, 41 Film Formers & Plasticizers, 41 Granulation, 37 Topical, 30 Parenteral, 29 Lubricants & Glidants, 24 Chewable & Orodispersible Aids, 19 Co-Processed Excipients, 14 Emulsifying Agents, 14 Rheology Modifiers, 10 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

123 Fillers, Diluents & Binders
68 Coating Systems & Additives
56 Controlled & Modified Release
53 Thickeners and Stabilizers
52 Direct Compression
51 Disintegrants & Superdisintegrants
48 Solubilizers
43 Taste Masking
41 Film Formers & Plasticizers
41 Granulation
37 Topical
30 Parenteral
29 Lubricants & Glidants
24 Chewable & Orodispersible Aids
19 Co-Processed Excipients
14 Emulsifying Agents
14 Rheology Modifiers
10 API Stability Enhancers
6 Surfactant & Foaming Agents
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 367 News #PharmaBuzz

1 Data Compilation #PharmaFlow
367 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 505 Regulatory FDF Prices, 25 Annual Reports

3 US Medicaid Prescriptions
505 Regulatory FDF Prices
25 Annual Reports

MARKET PLACE

84 APIs, 51 FDF Dossiers

84 APIs
51 FDF Dossiers

PATENTS & EXCLUSIVITIES

594 US Patents, 54 US Exclusivities, 17 Health Canada Patents

594 US Patents
54 US Exclusivities
17 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 11 Others

3 EDQM
3 USP
11 Others

ANALYTICAL

2 BioAnalytical Methods, 1 Analytical Methods

2 BioAnalytical Methods
1 Analytical Methods

$ API Ref.Price (USD/KG) : 4 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

594 All

01 100ASTRAZENECA AB

02 334BOEHRINGER INGELHEIM

03 116JANSSEN PHARMS

04 26MSD SUB MERCK

05 1SANTARUS INC

06 1SUN PHARM

07 16TAKEDA PHARMS USA

filter Patent Number Reset all filters

594 All

01 510022379*PED

02 1210258637*PED

03 410596120*PED

04 96515117

05 57326708

06 97407955

07 127579449

08 127713938

09 17780987

10 27785627

11 27807689

12 97919598

13 247943582

14 87943788

15 27959946

16 48080580

17 28173663

18 248222219

19 28288539

20 28414921

21 98501698

22 248513202

23 48551957

24 78628799

25 58673927

26 58685934

27 48716251

28 38846695

29 98883805

30 28900638

31 29101660

32 99155705

33 29173859

34 49308204

35 29320714

36 39339472

37 99415016

38 49439902

39 49555001

40 99616028

41 169949997

42 89949998

43 19962336

44 910022379

45 1210258637

46 410406172

47 1610596120

48 410610489

49 410610489*PED

50 310973827

51 310973827*PED

52 1211090323

53 1211090323*PED

54 311564886

55 411576894

56 411813275

57 2411833166

58 511911388

59 1212115179

60 96515117*PED

61 57326708*PED

62 97407955*PED

63 127579449*PED

64 127713938*PED

65 97919598*PED

66 87943582*PED

67 87943788*PED

68 88222219*PED

69 28414921*PED

70 98501698*PED

71 88513202*PED

72 48551957*PED

73 58673927*PED

74 58685934*PED

75 48716251*PED

76 38846695*PED

77 98883805*PED

78 59155705*PED

79 29173859*PED

80 59415016*PED

81 29555001*PED

82 99616028*PED

83 89949997*PED

84 89949998*PED

filter API Patent Reset all filters

594 All

01 121Y

02 473Blank

filter FDF Patent Reset all filters

594 All

01 222Y

02 372Blank

filter Expiration Date Reset all filters

594 All

01 22025-03-15

02 12025-03-23

03 242025-04-11

04 92025-05-02

05 22025-06-24

06 102025-07-13

07 92025-10-04

08 82025-10-11

09 92025-11-02

10 92025-11-26

11 92026-04-04

12 92026-05-26

13 42026-07-31

14 52026-11-24

15 22027-01-22

16 122027-04-15

17 72027-05-04

18 52027-05-24

19 92027-06-20

20 82027-07-14

21 122027-10-15

22 72027-11-04

23 242027-12-03

24 92027-12-20

25 82028-01-14

26 42028-03-21

27 82028-06-03

28 22028-06-27

29 22028-07-21

30 122028-08-01

31 42028-09-21

32 22029-01-21

33 122029-02-01

34 22029-02-03

35 242029-02-26

36 212029-04-02

37 22029-05-24

38 82029-08-26

39 132029-10-02

40 42029-10-14

41 92029-12-16

42 122030-02-11

43 52030-04-10

44 42030-04-14

45 92030-05-21

46 52030-05-26

47 32030-06-04

48 42030-06-15

49 92030-06-16

50 42030-07-06

51 42030-07-13

52 42030-09-30

53 82030-10-21

54 92030-11-12

55 52030-11-21

56 52030-11-26

57 32030-12-04

58 42031-03-30

59 92031-05-12

60 192032-03-07

61 42032-09-07

62 42033-03-06

63 22033-09-06

64 522034-04-03

65 162034-05-17

66 82034-06-11

67 242034-10-03

68 82034-11-17

69 82034-12-11

70 12035-05-01

Granules Metformin

Product Main Page

01

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-05-26

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8685934

Drug Substance Claim :

Drug Product Claim :

Application Number : 205649

Patent Use Code : U-1522

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2030-05-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

DCAT Week

Not Confirmed

ASTRAZENECA AB

DCAT Week

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!